Skip to main content
SpringerLink
Log in

New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

A Correction to this article was published on 20 November 2018

This article has been updated

Abstract

Recently several variants of clotting factors have shown a peculiar behavior so that they appear as new defects. The factors involved are FII, FV and FIX. Prothrombin deficiency is usually associated with bleeding. Recently a few prothrombin abnormalities involving Arg396 mutations, have been demonstrated to show antithrombin resistance with the consequent appearance of a thrombophilic state and venous thromboses in young age. The same is true for an abnormal FIX (FIX Padua). The thrombotic manifestations in the latter condition are also venous. The abnormal FIX (FIX Padua) is characterized by a great increase in FIX activity whereas FIX antigen is only slightly increased. The condition is due to an Arg338Lys mutation. The increased intrinsic clotting activity of this abnormal FIX is being investigated as a useful therapeutic approach in homophile B patients. Another new clotting disorder is represented by two abnormal FV (FV East Texas and FV Amsterdam). These are characterized by a deletion of part of the B domain of FV resulting in a “short” FV. The condition is characterized by a mild bleeding tendency due to high levels of Tissue Factor pathway inhibitor. The “short” factor V is in fact resistant to the action of Tissue Factor pathway inhibitor which is sharply increased in these patients. These new clotting entities have again demonstrated that the study of patients who show a tendency to venous thrombosis or a mild bleeding condition that cannot be explained on the basis of our current concepts of blood coagulation, may represent “new” coagulation disorders. All persons interested in thrombotic or hemorrhagic disorders should be informed about these new clinical and laboratory conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

  • 20 November 2018

    The original version of the article unfortunately contained few errors.

  • 20 November 2018

    The original version of the article unfortunately contained few errors.

  • 20 November 2018

    The original version of the article unfortunately contained few errors.

References

  1. Shmerling DH, Jung E, Duckert F (1960) Eine neue familiäre Koagulopathie infolge Mangels an fibrinstabilisierendem Faktor. Helv. paediat. Acta 15:171–175

    Google Scholar 

  2. Hougie C, Twomey JJ (1967) Haemophilia Bm: a new type of factor-IX deficiency. Lancet 1:698–700

    Article  CAS  Google Scholar 

  3. Girolami A, Molaro G, Lazzarin M, Scarpa R, Brunetti A (1970) A “new” congenital haemorrhagic condition due to the presence of an abnormal factor X (factor X Friuli): study of a large kindred. Br J Haematol 19:179–192

    Article  CAS  Google Scholar 

  4. Girolami A, Bareggi G, Brunetti A, Sticchi A (1974) Prothrombin padua: a “new” congenital dysprothrombinemia. J Lab Clin Med 84:654–666

    CAS  PubMed  Google Scholar 

  5. Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M (1979) Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 63:877–884

    Article  CAS  Google Scholar 

  6. Dahlbäck B, Carlsson M, and Svensson P J (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1; 90: 1004–1008.

    Article  Google Scholar 

  7. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67

    Article  CAS  Google Scholar 

  8. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703

    CAS  PubMed  Google Scholar 

  9. Miyawaki Y, Suzuki A, Fujita J, Maki A, Okuyama E, Murata M, Takagi A, Murate T, Kunishima S, Sakai M, Okamoto K, Matsushita T, Naoe T, Saito H, Kojima T (2012) Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 366:2390–2396

    Article  CAS  Google Scholar 

  10. Simioni P, Tormene D, Tognin G, Gavasso S, Bulato C, Iacobelli NP, Finn JD, Spiezia L, Radu C, Arruda VR (2009) X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 361:1671–1675

    Article  CAS  Google Scholar 

  11. Vincent LM, Tran S, Livaja R, Bensend TA, Milewicz DM, Dahlbäck B (2013) Coagulation factor V (A2440G) causes east Texas bleeding disorder via TFPIα. J Clin Invest 123:3777–3787

    Article  CAS  Google Scholar 

  12. Cunha ML, Bakhtiari K, Peter J, Marquart JA, Meijers JC, Middeldorp S (2015) A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood 125:1822–1825

    Article  CAS  Google Scholar 

  13. Girolami A, Scarano L, Saggiorato G, Girolami B, Bertomoro A, Marchiori A (1998) Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinol 9:557–569

    Article  CAS  Google Scholar 

  14. Lancellotti S, Basso M, De Cristofaro R (2013) Congenital prothrombin deficiency: an update. Semin Thromb Hemost 39:596–606

    Article  CAS  Google Scholar 

  15. Girolami A, Candeo N, Vettore S, Lombardi AM, Girolami B (2010) The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency. J Thromb Thrombol 29:299–302

    Article  Google Scholar 

  16. Djordjevic V, Kovac M, Miljic P, Murata M, Takagi A, Pruner I, Francuski D, Kojima T, Radojkovic D (2013) A novel prothrombin mutation in two families with prominent thrombophilia – the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost 11:1936–1939

    CAS  PubMed  Google Scholar 

  17. Kishimoto M, Suzuki N, Murata M, Ogawa M, Kanematsu T, Takagi A, Kiyoi H, Kojima T, Matsushita T (2016) The first case of antithrombin-resistant prothrombin Belgrade mutation in Japanese. Ann Hematol 95:541–542

    Article  Google Scholar 

  18. Sivasundar S, Oommen AT, Prakash O, Baskaran S, Biswas R, Nair S, Mohan CG, Biswas L (2013) Molecular defect of ‘Prothrombin Amrita’: substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding loop of prothrombin. Blood Cells Mol Dis 50:182–183

    Article  CAS  Google Scholar 

  19. Bulato C, Radu CM, Campello E, Gavasso S, Spiezia L, Tormene D, Simioni P (2016) New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. Arterioscler Thromb Vasc Biol 36:1022–1029

    Article  CAS  Google Scholar 

  20. Henriksen RA, Dunham CK, Miller LD, Casey JT, Menke JB, Knupp CL, Usala SJ (1998) Prothrombin Greenville, Arg517⟶Gln, identified in an individual heterozygous for dysprothrombinemia. Blood 91:2026–2031

    CAS  PubMed  Google Scholar 

  21. Kuang SQ, Hasham S, Phillips MD, Wolf D, Wan Y, Thiagarajan P, Milewicz DM (2001) Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas. Blood 97:1549–1554

    Article  CAS  Google Scholar 

  22. Broze GJ Jr, Girard TJ (2013) Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder. J Clin Invest 123:3710–3712

    Article  CAS  Google Scholar 

  23. Dahlbäck B (2016) Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hematol 38(Suppl 1):4–11

    Article  Google Scholar 

  24. Wood JP, Ellery PE, Maroney SA, Mast AE (2014) Biology of tissue factor pathway inhibitor. Blood 123:2934–2943

    Article  CAS  Google Scholar 

  25. Lozier JN. Gene therapy. Factor IX Padua: them that have, give. Blood. 2012: 29;120:4452–4453.

    Article  CAS  Google Scholar 

  26. Cantore A, Nair N, Della Valle P, Di Matteo M, Màtrai J, Sanvito F, Brombin C, Di Serio C, D’Angelo A, Chuah M, Naldini L, Vandendriessche T (2012) Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood 120:4517–4520.

    Article  CAS  Google Scholar 

  27. Monahan PE, Sun J, Gui T, Hu G, Hannah WB, Wichlan DG, Wu Z, Grieger JC, Li C, Suwanmanee T, Stafford DW, Booth CJ, Samulski JJ, Kafri T, McPhee SW, Samulski RJ (2015) Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther 26:69–81.

    Article  CAS  Google Scholar 

  28. Koenderman JS, Bertina RM, Reitsma PH, de Visser MC (2011) Factor IX-R338L (Factor IX Padua) screening in a Dutch population of sibpairs with early onset venous thromboembolism. Thromb Res 128:603

    Article  CAS  Google Scholar 

  29. de Moraes Mazetto B, Orsi FL, Siqueira LH, de Mello TB, de Paula EV, Annichino-Bizzacchi JM (2010) Prevalence of Factor IX-R338L (Factor IX Padua) in a cohort of patients with venous thromboembolism and mild elevation of factor IX levels. Thromb Res 126:165

    Article  Google Scholar 

  30. Girolami A, Tezza F, Scandellari R, Vettore S, Girolami B (2010) Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature. J Thromb Thrombol 30:172–178

    Article  CAS  Google Scholar 

  31. Girolami A, Cosi E, Santarossa C, Ferrari S, Luigia Randi M (2015) The story of serum prothrombin conversion accelerator, proconvertin, stable factor, cothromboplastin, prothrombin accelerator or autoprothrombin I, and their subsequent merging into factor VII. Semin Thromb Hemost 41:366–373

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by the Associazione Emofilia ed altre coagulopatie delle Tre Venezie.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Padua Medical School, Via Ospedale, 105, Padua, 35128, Italy

    A. Girolami, E. Cosi, S. Ferrari & A. M. Lombardi

  2. Division of Medicine, Padua City Hospital, Padua via G.Falloppio 2, Padua, 35128, Italy

    B Girolami

Authors
  1. A. Girolami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Cosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. M. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Girolami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Girolami.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Girolami, A., Cosi, E., Ferrari, S. et al. New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice. J Thromb Thrombolysis 44, 71–75 (2017). https://doi.org/10.1007/s11239-017-1488-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-017-1488-y

Keywords

Search

Navigation